{{Infobox drug
| IUPAC_name        = 7-Cyclopentyl-''N'',''N''-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7''H''-pyrrolo[2,3-d]pyrimidine-6-carboxamide
| image             = Ribociclib skeletal.svg
| alt               = 
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         = Kisqali
| Drugs.com         = {{Drugs.com|parent|kisqali}}
| MedlinePlus       = a617008
| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A/B/C/D/X/N -->
| pregnancy_category= 
| routes_of_administration = [[Oral_administration|By mouth]] (tablets)
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = Rx-only
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = 
<!-- Pharmacokinetic data -->
| bioavailability   = Unknown
| protein_bound     = ~70%
| metabolism        = Liver ([[CYP3A4|CYP3A4]])
| metabolites       = 
| onset             = 
| elimination_half-life = 32.0 (29.7–54.7) hrs
| duration_of_action= 
| excretion         = 69% feces, 23% urine
<!-- Identifiers -->
| CAS_number        = 1211441-98-3
| class             = 
| ATCvet            = 
| ATC_prefix        = L01
| ATC_suffix        = XE42
| PubChem           = 44631912
| DrugBank          = DB11730
| ChemSpiderID      = 30798107
| UNII              = TK8ERE8P56
| KEGG              = D10883
| ChEMBL            = 3545110
| synonyms          = LEE 011
<!-- Chemical and physical data -->
| chemical_formula  = 
| C=23 | H=30 | N=8 | O=1
| molecular_weight  = 
| smiles = CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5
| StdInChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
| StdInChIKey = RHXHGRAEPCAFML-UHFFFAOYSA-N
}}
'''瑞博西利'''（{{lang-en|Ribociclib}}）商品名'''擊癌利'''（KISQALI）是一種[[CDK4|CDK4]]/[[CDK6|6]]抑制劑類型的[[乳腺癌|乳腺癌]]藥物<ref name="Drugs.com">{{Drugs.com|pro|kisqali}} on Kisqali. Accessed 2017-09-08.</ref><ref name=Samson2014>{{cite journal |last1=Samson |first1=Kurt |title=LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers |journal=Oncology Times |volume=36 |issue=3 |year=2014 |pages=39–40 |doi=10.1097/01.COT.0000444043.33304.c1 }}</ref>，由[[Astex|Astex]]和[[诺华|诺华]]制药研发<ref>{{cite news|url=https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-granted-fda-priority-review-first-line-treatment|title=Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer|publisher=[[Novartis|Novartis]]|date=2016-11-01}}</ref>。可使用的對象為：賀爾蒙接受體陽性、[[HER2/neu|HER2]]陰性患者，以及停經後晚期乳腺癌患者。

==参考文献==
{{reflist}}

{{化疗药物}}

[[Category:蛋白激酶抑制剂|Category:蛋白激酶抑制剂]]
[[Category:氨甲酰|Category:氨甲酰]]
[[Category:吡啶|Category:吡啶]]
[[Category:嘧啶|Category:嘧啶]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:环戊基化合物|Category:环戊基化合物]]